← BioTransfer GEO Dataset Finder
GEO series

Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib or belumosudil in murine sclerodermatous GvHD

GSE284107 Mus musculus (mouse) RNA-seq (gene expression) 15 samples Submitted 2025/04/02 Platform GPL24247
At a glance

RNA-seq (gene expression) · mouse · 15 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Mus musculus (mouse)
Samples
15 samples: 4 × Syngeneic vs 4 × Allogeneic treated Wnt-C59 vs 4 × Allogeneic treated Wnt-C59 + belumosudil vs 3 × AllogeneicGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHDBlood advances · 2025
Summary (written by the submitters)
Chronic graft-versus-host disease (cGvHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (alloSCT) and is associated with high morbidity and mortality. First drugs have been recently approved for the treatment of cGvHD, but the response rates are suboptimal and treatment discontinuation due to side effects remains frequent.
Read the full summary ↓
Here, we evaluated the efficacy and safety profile of porcupine inhibition by Wnt-C59 in monotherapy or in combination with ruxolitinib, ibrutinib or belumosudil in experimental sclerodermatous GvHD (sclGvHD). Treatment was well tolerated in all groups with improvements in clinical and histological features. Of these, ruxolitinib in monotherapy, and the combination therapies demonstrated the highest efficacy. The combination therapies of Wnt-C59 with ibrutinib or belumosudil showed additive antifibrotic effects in skin and lungs compared to the respective monotherapies. Our study may have direct translational relevance, since: 1) core signaling pathways targeted by these drugs were enriched in both human and murine sclGvHD, and 2) ruxolitinib, ibrutinib and belumosudil are already approved for the treatment of cGvHD, and porcupine inhibitors are in clinical trials for other fibrotic diseases. Thus, simultaneous targeting of different pathogenetically relevant pathways might be a safe and effective therapeutic approach in sclGvHD.
Published in
Combination therapies of porcupine inhibition with ruxolitinib, ibrutinib, or belumosudil in murine sclerodermatous GVHD
Hong X, Xiao Y, Xu L et al. · Blood advances 2025 · PMID 39775728 · doi:10.1182/bloodadvances.2024014387
This dataset
Open GSE284107 in finder → Find more mouse RNA-seq datasets →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE284107_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1197368 and SRA study SRP551046. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 39775728) ↗
Study design
4 × Syngeneic vs 4 × Allogeneic treated Wnt-C59 vs 4 × Allogeneic treated Wnt-C59 + belumosudil vs 3 × Allogeneic

Supports a between-group comparison across 15 samples.

How we read this: 4 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
Datasets on a similar topic

Search all mouse RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.